Linksbridge SPC

Linksbridge expands the capacity of NGOs, IGOs, and nonprofits to improve human lives.

[Linksbridge SPC @linksbridge]

Linksbridge will no longer post updates on this platform. We invite you to follow us on LinkedIn or Bluesky. Visit our website for more. ✌🏽

[Linksbridge SPC @linksbridge]

Just four days after an Ebola outbreak was declared in Uganda, a trial to evaluate a vaccine against the disease has begun. This week's highlights explore the rapid launch of the study and more.

https://t.co/2z8Tye5PzS

[Linksbridge SPC @linksbridge]

Essential medicines remain unavailable and unaffordable for a large portion of the world—an "important violation of human rights" that requires urgent, comprehensive action—according to a new analysis out this month.
https://t.co/OySeExzFYH

[Linksbridge SPC @linksbridge]

The U.S. government recently doled out fresh funding for pandemic vaccine and therapeutic development, a tranche of which will go to Moderna for an mRNA-based H5N1 influenza vaccine.

https://t.co/m8v4lsoqNn

[Linksbridge SPC @linksbridge]

Since 2019, Linksbridge has tracked over 180 planned integrated campaign deliveries—including Madagascar's polio/measles vaccination effort.

Linksbridge's Campaigns Hub provides health campaign data for over 20 interventions. Access it here: https://t.co/gOQG3hGeQW

[Gates Foundation @gatesfoundation]

Madagascar successfully vaccinated millions of children against polio & measles this fall, protecting them from the devastating, preventable diseases. Through integrated efforts such as these, a healthier, polio-free world is #HumanlyPossible. Learn more: https://t.co/nzz4OOWkGb

[Linksbridge SPC @linksbridge]

Regional manufacturing efforts got a boost in recent days via two initiatives aiming to drive local PCV production. More on these initiatives and other pharma news important to global health in this week’s highlights. https://t.co/p5rt4rI8Ch

[Linksbridge SPC @linksbridge]

In 2022, Linksbridge collaborated with the Gates Foundation and other stakeholders to create materials in support of the market entry and scale-up of Wolbachia replacement technology. The forecast's methods and results are available as global public goods: https://t.co/5pCPxEQHzU

[Wellcome @wellcometrust]

The @WMPglobal has helped protect more than 11 million people in 14 countries from diseases like dengue. How?

By growing millions of mosquitoes.

@ScottLOneill, the programme’s founder, explains how their method works in ‘Behind the Research’ ⤵️
https://t.co/yyAoeit5lK

[Linksbridge SPC @linksbridge]

Nigeria has launched its first malaria vaccination campaign for children. More on this effort and campaigns across Africa, Asia, and Latin America in our latest health campaigns roundup. https://t.co/aULrggzqIT

[Linksbridge SPC @linksbridge]

Progress for malaria control and elimination efforts were key themes in our first issue of 2025. Explore these developments and more in this week's highlights.

https://t.co/yBWgN9PsKm

[Linksbridge SPC @linksbridge]

Our last issue of 2024 covers a little bit of everything. We highlight mpox vaccine manufacturing, promising Phase 2b results for a blood-stage malaria vaccine, news from Institut Pasteur de Dakar's centenary celebration, and more.
https://t.co/VsHsBwjhiZ

[Linksbridge SPC @linksbridge]

WHO has granted prequalification to the first test for TB diagnosis and antibiotic susceptibility testing. In this week's highlights, we explore this critical milestone, the first regulatory nod for moxidectin in a river blindness-endemic country, and more.https://t.co/FpAgVpIP3w

[Linksbridge SPC @linksbridge]

In this month's roundup of campaign news, we highlight polio and cholera outbreak response efforts, integrated campaigns delivering vaccines, vitamin A supplements and deworming treatments, and HPV campaigns targeting children in Africa and Asia.
https://t.co/rml6k4szRK

[Linksbridge SPC @linksbridge]

This week’s highlights explore promising clinical trial results for a novel TB regimen, Unitaid’s pledge to accelerate access to HIV PrEP drug lenacapavir, funds for global health vaccine R&D, developments in the African manufacturing space, and more. https://t.co/Kp2KijuqOv

[Linksbridge SPC @linksbridge]

Drug and vaccine R&D investments were front and center in this week's highlights. Dyadic won backing for malaria and RSV mAbs development, Insud scored funds for a postpartum hemorrhage treatment trial in LMICs, and more.
https://t.co/iLgL2oZGp4

[Linksbridge SPC @linksbridge]

Novartis dethroned eight-time-front-runner GSK in the 2024 Access to Medicine Index. In this week’s highlights, we dive into AtM's ranking of leading pharma companies’ efforts to provide access to their products in LMICs and more. https://t.co/PSITkp8gkz

[Linksbridge SPC @linksbridge]

New trials for mpox countermeasures are in the works. Catch up on these developments and other news related to H5N1, HIV, TB and TCV in this week's highlights. https://t.co/FTTbGXzfuR

[Linksbridge SPC @linksbridge]

In this month's roundup of campaign news, we highlight polio vaccination campaigns in Afghanistan, Kenya, Pakistan, and Uganda and spotlight integrated campaigns in Nigeria. https://t.co/ZPwq48F19c

[Linksbridge SPC @linksbridge]

WHO released a list identifying 17 endemic pathogens as top priorities for new vaccine development. More on the list and other pharma news important to global health in this week's highlights.
https://t.co/jToTeZqtLk

[Linksbridge SPC @linksbridge]

Several malaria-related news items caught our eye this week: MMV launched a first-in-human trial of a potential "game changer" antimalarial and WHO prequalified GSK's P. vivax treatment tafenoquine. More, in this week's highlights. https://t.co/tTogGUcZF4

[Linksbridge SPC @linksbridge]

In this week's highlights, we cover Rwanda's launch of the first clinical trial of a Marburg virus treatment, WHO's prequalification of a fourth TCV, the U.S. FDA's expanded approval of Pfizer's RSV vaccine, and more.
https://t.co/voul8CDzZu